News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

KaloBios Pharmaceuticals, Inc. to Present at Credit Suisse Antibody Conference


5/9/2013 6:28:13 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SOUTH SAN FRANCISCO, Calif., May 8, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (NASDAQ:KBIO) today announced that the company will present at the Credit Suisse Antibody Conference, to be held in New York City on May 10, 2013. KaloBios President and Chief Executive Officer, David W. Pritchard, will provide an overview of KaloBios and the company's three current clinical programs for its proprietary, patient-targeted monoclonal antibody therapeutics.

(Logo: http://photos.prnewswire.com/prnh/20130225/MM66380LOGO)

Company Presentation:
When: Friday, May 10, 2013, 10:30AM Eastern Time
Where: One Madison Avenue at 24th Street, New York, NY

About KaloBios

KaloBios Pharmaceuticals, Inc. is developing a portfolio of patient-targeted, first-in-class monoclonal antibodies to treat serious medical conditions with a primary clinical focus on respiratory diseases and cancer. For more information on KaloBios Pharmaceuticals, please visit our web site at http://www.kalobios.com.

Contact:
Jeffrey H. Cooper
Chief Financial Officer
KaloBios Pharmaceuticals, Inc.
(650) 243-3146
ir@kalobios.com

Media Contact:
Joan E. Kureczka
Kureczka/Martin Associates
Tel: (415) 821-2413
Mobile: (415) 690-0210
Joan@Kureczka-Martin.com

SOURCE KaloBios Pharmaceuticals, Inc.

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES